Effectiveness of Casirivimab-Imdevimab and Sotrovimab During a SARS-CoV-2 Delta Variant Surge: A Cohort Study and Randomized Comparative Effectiveness Trial.
Sign Up to like & getrecommendations! Published in 2022 at "JAMA network open"
DOI: 10.1001/jamanetworkopen.2022.20957
Abstract: Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-CoV-2 Delta variant. Objective To evaluate the effectiveness of mAb against the Delta… read more here.
Keywords: casirivimab imdevimab; imdevimab; effectiveness; mab treatment ... See more keywords
Virologic Efficacy of Casirivimab and Imdevimab COVID-19 Antibody Combination in Outpatients With SARS-CoV-2 Infection
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.25411
Abstract: Key Points Question Can casirivimab and imdevimab effectively reduce the viral load of SARS-CoV-2 with lower doses and a subcutaneous route of administration? Findings In this phase 2 randomized clinical trial of outpatients with SARS-CoV-2,… read more here.
Keywords: administration; outpatients sars; casirivimab imdevimab; imdevimab ... See more keywords
Association of Subcutaneous or Intravenous Administration of Casirivimab and Imdevimab Monoclonal Antibodies With Clinical Outcomes in Adults With COVID-19
Sign Up to like & getrecommendations! Published in 2022 at "JAMA Network Open"
DOI: 10.1001/jamanetworkopen.2022.6920
Abstract: Key Points Question Is subcutaneous treatment with casirivimab and imdevimab associated with improved 28-day clinical outcomes compared with nontreatment, and is it clinically similar to intravenously administered casirivimab and imdevimab for outpatients with COVID-19? Findings… read more here.
Keywords: clinical outcomes; casirivimab; casirivimab imdevimab; hospitalization death ... See more keywords
Casirivimab/Imdevimab: First Approval
Sign Up to like & getrecommendations! Published in 2021 at "Drugs"
DOI: 10.1007/s40265-021-01620-z
Abstract: Casirivimab/imdevimab (Ronapreve™; REGEN-COV™) is a co-packaged combination of two neutralizing immunoglobulin gamma 1 (IgG1) human monoclonal antibodies (casirivimab and imdevimab) against the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative… read more here.
Keywords: imdevimab; treatment; covid; casirivimab imdevimab ... See more keywords
Outpatient Use of Monoclonal Antibodies Casirivimab and Imdevimab in Pregnancy for Mild-to-Moderate Coronavirus Disease 2019
Sign Up to like & getrecommendations! Published in 2023 at "American Journal of Perinatology"
DOI: 10.1055/s-0042-1753488
Abstract: Abstract Objective The aim of this study was to report the use casirivimab/imdevimab therapy in pregnant women with moderate coronavirus disease 2019 (COVID-19). Study Design We report 12 cases of unvaccinated pregnant patients with mild-to-moderate… read more here.
Keywords: mild moderate; disease; casirivimab imdevimab; moderate covid ... See more keywords
512. Does Time From COVID-19 Symptom Onset to Administration of Anti-spike Protein Monoclonal Antibody Predict Response?
Sign Up to like & getrecommendations! Published in 2021 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofab466.711
Abstract: Abstract Background Casirivimab/imdevimab is a monoclonal antibody (mAb) cocktail with emergency use authorization for mild-to-moderate coronavirus disease 2019 (Covid-19) in patients at high risk for severe disease progression and/or hospitalization. Little is known about the… read more here.
Keywords: monoclonal antibody; symptom onset; early administration; grant research ... See more keywords
Combination Therapy With Casirivimab/Imdevimab and Remdesivir for Protracted SARS-CoV-2 Infection in B-cell-Depleted Patients
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac064
Abstract: Abstract Profoundly B-cell-depleted patients can have prolonged severe acute respiratory syndrome coronavirus 2 infections with evidence of active viral replication, due to inability to mount an adequate humoral response to clear the virus. We present… read more here.
Keywords: imdevimab remdesivir; depleted patients; infection; cell depleted ... See more keywords
Comparative Efficacy of Early COVID-19 Monoclonal Antibody Therapies: A Retrospective Analysis
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac080
Abstract: Abstract Background Bamlanivimab and casirivimab/imdevimab are monoclonal antibody (mAb) treatments used for mild to moderate coronavirus disease 2019 (COVID-19) in high-risk patients. To date, there are few data summarizing real-world evidence comparing the 2 mAbs.… read more here.
Keywords: casirivimab imdevimab; monoclonal antibody; covid; efficacy ... See more keywords
Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac093
Abstract: Abstract Background The increasing use of monoclonal antibodies (mAbs) to treat coronavirus disease 2019 raises questions about their impact on the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mAb-resistant variants. We assessed the… read more here.
Keywords: delta variant; sars cov; load; casirivimab imdevimab ... See more keywords
Effectiveness of Casirivimab-Imdevimab Monoclonal Antibody Treatment Among High-Risk Patients With Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617.2 (Delta Variant) Infection
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac186
Abstract: Abstract Summary Retrospective analysis of the post–propensity score (PS)–matched cohort of 8426 outpatients balanced in clinical and demographic covariates showed that treatment with casirivimab-imdevimab monoclonal antibody was effective against the SARS-CoV-2 Delta variant to reduce… read more here.
Keywords: imd mab; cas imd; delta variant; casirivimab imdevimab ... See more keywords
1144. Rate of Infusion Reactions Among Patients Receiving Casirivimab/Imdevimab in the Home Setting
Sign Up to like & getrecommendations! Published in 2022 at "Open Forum Infectious Diseases"
DOI: 10.1093/ofid/ofac492.982
Abstract: Abstract Background Monoclonal antibodies used in the treatment and prevention of COVID 19 infection are an emerging area of infectious disease. Casirivimab/imdevimab received emergency use authorization (EUA) for the prophylaxis and treatment of COVID 19… read more here.
Keywords: infusion reactions; infusion time; casirivimab imdevimab; rate ... See more keywords